- Senate passes Drug Quality and Security Act
- FDA approves generic versions of Cymbalta
- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- Diplomat becomes distributor of recently approved cancer drug
BETHESDA, Md. A Food and Drug Administration advisory committee has voted to recommend expanding the use of an Eli Lilly & Co. pain drug, the drug maker said Thursday.
Lilly said the FDA’s Anesthetic and Life Support Drugs Advisory Committee voted to recommend approval of Cymbalta (duloxetine hydrochloride) as a treatment for chronic lower back pain, though it did not support the drug as a treatment for chronic pain due to osteoarthritis. The drug currently is approved for treating diabetic peripheral neuropathic pain and fibromyalgia.
The advisory committee’s vote does is not binding, though the FDA will take it into account when deciding whether to approve the new uses for the drug.